TFXMay 7, 2026 at 10:30 AM UTCHealth Care Equipment & Services

Teleflex Q1 Revenue Meets Guidance, GAAP Loss Reflects Transformation Costs

Read source article

What happened

Teleflex's first-quarter 2026 revenue from continuing operations rose 32.3% year-over-year to $548.3 million, or 5.1% on a pro forma adjusted constant currency basis, within the company's full-year guidance range. However, GAAP diluted EPS from continuing operations was a loss of $0.11, compared to a gain of $1.14 a year earlier, driven by stranded costs and restructuring charges related to the planned divestitures. The results are in line with the company's reset expectations, with the core business showing steady procedural demand while the financial drag from the separation process weighs on reported profits. Management affirmed its full-year 2026 outlook, including adjusted diluted EPS of $6.25-$6.55, which excludes any benefit from the $1.0 billion share repurchase authorization. The stock at ~$122 remains priced for a trough earnings year, with the key catalysts—divestiture closings and capital return—still dependent on regulatory timing in the second half of 2026.

Implication

Over the next 6-12 months, the investment case hinges on three proof points: (1) divestitures close by the September 1, 2026 outside dates, (2) quarterly data shows RemainCo sustaining 4.5%-5.5% constant currency growth, and (3) proceeds are deployed into buybacks and debt paydown. The Q1 revenue prints support the growth narrative, but no pull-forward on capital return means upside is capped. Investors should maintain a WAIT posture, with an attractive entry near $110 and a trim level above $150.

Thesis delta

No material change. The Deep Value thesis of a timing-dependent catalyst stack remains intact, with Q1 results providing incremental evidence that the underlying business is on track but no confirmation on the key catalysts (deal closings and buyback execution). The GAAP loss underscores the transition noise, but adjusted metrics are within guided ranges. The next 90-day checkpoint will be the Q2 update, where any shift in deal timing language would be a thesis breaker.

Confidence

Medium